London · Delayed Price · Currency is GBP · Price in USD Xeris Biopharma Holdings Company Description
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 394 |
| CEO | John Shannon |
Contact Details
Address: 1375 West Fulton Street Chicago, Illinois 60607 United States | |
| Phone | 844 445 5704 |
| Website | xerispharma.com |
Stock Details
| Ticker Symbol | 0A8E |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US98422E1038 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Shannon | Chief Executive Officer and Director |
| Kevin McCulloch | President and Chief Operating Officer |
| Steven M. Pieper | Chief Financial Officer |
| Beth P. Hecht J.D. | Chief Legal Officer and Corporate Secretary |
| Allison Wey | Senior Vice President of Investor Relations and Corporate Communications |
| Brian Conner | SVice President of Quality and Chief Compliance and Risk Officer |
| Kendal Korte | Senior Vice President of Human Resources |
| Dr. Anh Nguyen M.B.A., M.D. | Chief Medical Officer |